Please assess the completion status of the following clinical trial:

Trial Title: REPEAT Study - Resistance to ErythroPoietin Effectiveness Algorithm Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent~* Adult patients \> 18 years old with current Epoetin Alpha dose \>250 units/kg/wk~* Hemoglobin \>90g/L or \<130g/L~* Patients whom a temporary fall in Hb of up to 10g/L is deemed safe~* Patients not expected to have a change in the type of Epo or route of Epo therapy for the duration of the Study period~Exclusion Criteria:~* Known iron deficiency (% saturation \<20 or ferritin \<100)~* Vit B12 or folate deficiency (levels below normal limit for centre lab)~* Known malignancy (solid organ, leukemia or multiple myeloma)~* Jehovah's witness patients/those who refuse transfusion~* Expected to die in the next 6 months~* On dialysis less than 3 months~* Temporary (not tunneled) dialysis access catheter~* Pure red cell aplasia~* High likelihood of early withdrawal or interruption of the study (eg. severe or unstable coronary artery disease, stroke, severe liver disease within the 12 weeks before screening)~* Planned major elective surgery during the study period~* Pregnancy or breast-feeding~* Women of child-bearing potential without effective contraception (abstinence, oral contraceptives, diaphragm, IUD)~* Administration of another investigational drug within 4 weeks before screening or planned during study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: NO_INTERVENTION): Epo dose to remain constant throughout study
- Dosage Decrease Arm (Type: ACTIVE_COMPARATOR): Arm 2 is to have an decrease of erythropoietin at regular intervals.

Based on this trial design, predict the completion outcome and termination type (if applicable).